Healthcare, biopharma and wellness industry executives offered a positive but measured response to Union Budget 2026, saying its emphasis on mental healthcare, pharmaceutical manufacturing, medical education and preventive care could reshape the sector over time, even as outcomes will depend on sustained investment and execution.
In post-Budget reactions, industry leaders said the government appeared to be signalling a structural approach to healthcare, with initiatives spanning infrastructure creation, workforce expansion and domestic manufacturing, rather than short-term spending increases alone.
One of the most closely watched announcements was the government’s decision to establish new national-level mental healthcare institutions. The move comes amid rising awareness of mental health needs in India, where access to trained professionals and specialised facilities remains limited, particularly outside major urban centres.
“Delighted to see the budget acknowledging the mental healthcare ecosystem in India and announcing new national-level mental healthcare institutions aimed at improving care delivery, training and research,” said Abhineet Kumar, CEO and founder of Rocket Health.
Kumar said the announcement marked an important starting point for strengthening mental healthcare infrastructure. “It’s a strong start and will go a long way in developing the mental healthcare infrastructure in our country,” he said.
Alongside mental health, the Budget also outlined steps to expand pharmaceutical manufacturing capacity and increase the number of medical education seats, measures aimed at addressing doctor shortages and improving access to care.
“I’m glad we are also doubling down in pharma manufacturing and expanding medical seats to address doctor shortages — both much needed steps to improve access for our billion strong population and strengthen India’s position as a global healthcare leader,” Kumar added.
India has long faced a mismatch between healthcare demand and workforce availability, with uneven distribution of doctors and specialists across regions. Industry analysts say expanding training capacity is a necessary, though gradual, solution, as it takes years for new medical graduates to enter the workforce.
Executives in the biopharma and digital health segments also pointed to the Budget’s broader focus on innovation and disease management. Saurav Kasera, co-founder and CEO of CLIRNET and DocTube, said strategic investment in biopharma and healthcare could have far-reaching implications.
“Strategic investment in biopharma and healthcare is a defining step in transforming India into the therapeutic storehouse of the world,” Kasera said.
He pointed to priorities such as innovation for non-communicable diseases, next-generation training for allied health professionals and the development of global medical tourism hubs.
“By prioritizing innovative solutions for non-communicable diseases, strengthening next-generation training for allied health professionals, and developing global medical tourism hubs, India can build resilient, inclusive healthcare from the grassroots up,” he said.
Kasera added that such an approach could generate employment, reduce pressure on tertiary care facilities and support domestic innovation.
“This will generate employment, reduce tertiary care burden, drive domestic innovation, and position healthcare as a cornerstone in achieving the government’s vision of capturing 10% of the global services market,” he said.
Non-communicable diseases such as diabetes, cardiovascular conditions and cancer account for a growing share of India’s disease burden, increasing demand for long-term care, specialised treatment and preventive interventions.
Industry participants say this trend shows the need for integrated care models and sustained investment in both primary and secondary healthcare systems.
The Budget’s biopharma announcements also drew attention from wellness-focused companies. Arun Ramamurthy, co-founder of Staywell.Health, said the government’s intent to increase investment in biopharma could have longer-term cost and access implications.
“The Indian Government intends to increase investment in its biopharma sector through various initiatives such as the Biopharma, Shakti’ fund (which is Rs. 10,000 crore) along with improving the affordability of medicines used in treating chronic diseases,” Ramamurthy said.
“This investment will serve to lower healthcare costs over time,” he added.
Union Budget 2026 emphasis on preventive care
Ramamurthy also pointed to the Budget’s emphasis on preventive care and traditional healthcare systems as part of a broader shift in policy orientation.
“Investing more in preventive care, traditional health care modalities (Ayurveda and Yoga) and increasing the total number of places of care will change the focus of healthcare from being solely reactively treated too much more integratively-treat/ integrated wellness based over a long time frame,” he said.
According to him, such a transition could reduce pressure on existing healthcare infrastructure and improve long-term health outcomes. “Ultimately decreasing stress on the existing healthcare delivery system/infrastructure and improving health risk outcomes throughout the overall healthcare insurance delivery system,” he said.
Industry executives cautioned, however, that translating Budget announcements into tangible improvements would require coordination between central and state governments, regulatory clarity and adequate funding over multiple years. Mental healthcare institutions, in particular, will need trained professionals and sustainable operating models to meet growing demand.
